Regulatory clearances dominated the health and bio agenda, with two London-listed pharmaceutical stories advancing key products through European approval processes on the same day. Futura Medical secured clearance for a next-generation erectile dysfunction gel, while AstraZeneca and partner Daiichi Sankyo landed EU approval for a breast cancer therapy backed by a meaningful survival benefit in late-stage trial data.
Futura Medical clears path for Eroxon Intense launch
Futura Medical (AIM:FUM) has completed all design, validation and pre-market regulatory steps required to launch Eroxon Intense across the European Economic Area and UK, clearing the new formulation under its existing CE certification against the EU Medical Device Regulation and its UKCA certification. The announcement lifted shares 4.27% to 0.3952p. The clearance opens the door for commercial partner Cooper Consumer Health to bring the faster-acting, higher-sensation variant to market across its licensed EEA and UK territories, extending a franchise built on the original Eroxon gel.
Eroxon Intense was developed in response to user feedback seeking a more rapid onset and stronger sensation than the original formulation. A Home User Test involving 223 men, reported in March, found satisfactory erection hardness in around 70% of sexual encounters and successful intercourse in approximately 85%, with more than half of participants saying they would likely buy the product. Futura still expects US FDA clearance for the original Eroxon in the second half of the year, after which it intends to work with new US partner MPG toward a 2027 American launch.
"This approval follows a series of positive studies demonstrating strong consumer acceptance, ease of use and real-world performance," said Alex Duggan, chief executive of Futura Medical.
The clearance matters beyond the immediate product news: it gives Futura a second commercial lever within the same regulatory footprint, rather than requiring a fresh approval pathway, and hands Cooper Consumer Health an additional variant to drive Eroxon brand growth in Europe and the UK ahead of any US launch. For a company whose cash runway depends on licensing and royalty momentum, broadening the addressable franchise in already-approved territories reduces reliance on the FDA timeline as the sole near-term catalyst.
Datroway secures EU approval in triple-negative breast cancer
AstraZeneca (LSE:AZN) and Daiichi Sankyo's Datroway (datopotamab deruxtecan) has won European Commission approval as a first-line monotherapy for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 immunotherapy. The approval follows a positive opinion from the European Medicines Agency's advisory committee and rests on Phase III TROPION-Breast02 data presented at the 2025 European Society for Medical Oncology Congress, arriving as AstraZeneca shares slipped 0.74% to 12626.0p.
The trial results underpinning the approval were substantial: patients on Datroway had a median overall survival of 23.7 months against 18.7 months for chemotherapy, a statistically significant five-month improvement, alongside a 43% reduction in the risk of disease progression or death and an objective response rate of 62.5% versus 29.3% for chemotherapy. "Every year, more than 80,000 people in Europe are diagnosed with triple-negative breast cancer, a disease that often affects younger women and has treatment options in the metastatic setting," said Dave Fredrickson, president at Datroway, adding that "today's approval of Datroway brings an antibody drug conjugate with a differentiated clinical profile underpinned by a strong survival benefit to people with this aggressive disease."
The approval extends Datroway's label into a difficult-to-treat cancer subtype where options for patients ineligible for immunotherapy have been, reinforcing the drug's role within AstraZeneca's oncology portfolio and Daiichi Sankyo's antibody-drug conjugate franchise. With a clear survival advantage over chemotherapy now embedded in the EU label, the approval strengthens the commercial case for Datroway across other markets still reviewing similar filings.
Read the story →
